Genprex (GNPX) Operating Expenses (2016 - 2026)
Genprex (GNPX) posted quarterly Operating Expenses of $118635.0 for Q1 2026, down 35.79% year-over-year from $184773.0 in Q1 2025, and down 99.2% quarter-over-quarter from $14.9 million in Q4 2025.
Genprex (GNPX) Operating Expenses (2016 - 2026) Analysis & Trends
Genprex's Operating Expenses history runs 11 years deep, the most recent figure standing at $118635.0 for Q1 2026.
- In Q1 2026, Operating Expenses fell 35.79% year-over-year to $118635.0; the TTM figure through Mar 2026 stood at $15.4 million (down 25.77% YoY), while the FY2025 annual figure was $15.5 million, down 26.72% from the prior year.
- Operating Expenses for Q1 2026 stood at $118635.0, down from $14.9 million in the prior quarter.
- The five-year high for Operating Expenses was $18.1 million in Q4 2024, with the low at $19553.0 in Q3 2025.
- The 5-year median for Operating Expenses is $5.8 million (2022), against an average of $5.4 million.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses jumped 203.83% in 2024, then tumbled 95.36% in 2025.
- Genprex's Operating Expenses stood at $6.6 million in 2022, then fell by 9.29% to $6.0 million in 2023, then surged by 203.83% to $18.1 million in 2024, then retreated by 18.09% to $14.9 million in 2025, then sank by 99.2% to $118635.0 in 2026.
- Business Quant data shows GNPX's Operating Expenses at $118635.0 in Q1 2026, $14.9 million in Q4 2025, and $19553.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 541.02 Mn |
| 10 | Genprex | 1.88 Mn | -13.27 Mn | - | 68,354.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118,635.00 |
| Dec 31, 2025 | 14.85 Mn |
| Sep 30, 2025 | 19,553.00 |
| Jun 30, 2025 | 458,917.00 |
| Mar 31, 2025 | 184,773.00 |
| Dec 31, 2024 | 18.13 Mn |
| Sep 30, 2024 | 421,498.00 |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 545,384.00 |
| Dec 31, 2023 | 5.97 Mn |
| Sep 30, 2023 | 7.79 Mn |
| Jun 30, 2023 | 8.04 Mn |
| Mar 31, 2023 | 9.26 Mn |
| Dec 31, 2022 | 6.58 Mn |
| Sep 30, 2022 | 6.17 Mn |
| Jun 30, 2022 | 5.77 Mn |
| Mar 31, 2022 | 5.31 Mn |
| Dec 31, 2021 | 6.75 Mn |
| Sep 30, 2021 | 3.44 Mn |
| Jun 30, 2021 | 3.99 Mn |